Stock Analysis
- United States
- /
- Pharma
- /
- NasdaqGS:ZVRA
Zevra Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Zevra Therapeutics (NASDAQ:ZVRA) Second Quarter 2024 Results
Key Financial Results
- Revenue: US$4.45m (down 48% from 2Q 2023).
- Net loss: US$19.9m (loss widened by 292% from 2Q 2023).
- US$0.48 loss per share (further deteriorated from US$0.15 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Zevra Therapeutics Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) missed analyst estimates by 9.9%.
Looking ahead, revenue is forecast to grow 48% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are down 5.4% from a week ago.
Risk Analysis
It is worth noting though that we have found 2 warning signs for Zevra Therapeutics (1 shouldn't be ignored!) that you need to take into consideration.
Valuation is complex, but we're here to simplify it.
Discover if Zevra Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:ZVRA
Zevra Therapeutics
Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States.